Your browser doesn't support javascript.
loading
The macro-evolutionary events in esophageal squamous cell carcinoma.
Yang, Bin; Yan, Ting; Cui, Heyang; Xu, Enwei; Ma, Yanchun; Cheng, Caixia; Zhang, Ling; Kong, Pengzhou; Wang, Fang; Qian, Yu; Yang, Jian; Li, Yaoping; Li, Hongyi; Bi, Yanghui; Hu, Xiaoling; Wang, Juan; Song, Bin; Yang, Jie; Gao, Wei; Liu, Jing; Zou, Binbin; Shi, Ruyi; Zhang, Yanyan; Liu, Haiyan; Liu, Yiqian; Zhai, Yuanfang; Chang, Lu; Wang, Yi; Zhang, Yingchun; Jia, Zhiwu; Chen, Xing; Xi, Yanfeng; Li, Guodong; Liang, Jianfang; Guo, Jiansheng; Guo, Shiping; Zhang, Rongsheng; Cheng, Xiaolong; Cui, Yongping.
Afiliação
  • Yang B; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Yan T; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Cui H; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Xu E; Department of Tumor Surgery, Shanxi Cancer Hospital, Taiyuan, Shanxi, China.
  • Ma Y; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Cheng C; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Zhang L; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Kong P; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Wang F; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Qian Y; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Yang J; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Li Y; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Li H; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Bi Y; Department of Pathology, Shanxi Cancer Hospital, Taiyuan, Shanxi, China.
  • Hu X; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Wang J; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Song B; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Yang J; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Gao W; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Liu J; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Zou B; Department of Pathology, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Shi R; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Zhang Y; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Liu H; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Liu Y; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Zhai Y; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Chang L; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Wang Y; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Zhang Y; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Jia Z; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Chen X; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Xi Y; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Li G; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Liang J; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Guo J; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Guo S; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Zhang R; Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Cheng X; Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
  • Cui Y; Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China.
Oncotarget ; 8(68): 112770-112782, 2017 Dec 22.
Article em En | MEDLINE | ID: mdl-29348864
ABSTRACT
Understanding the evolutionary processes operative in cancer genome may provide insights into clinical outcome and drug-resistance. However, studies focus on genomic signatures, especially for macro-evolutionary events, in esophageal squamous cell carcinoma (ESCC) are limited. Here, we integrated published genomic sequencing data to investigate underlying evolutionary characteristics in ESCC. We found most of ESCC genomes were polyploidy with high genomic instability. Whole genome doubling that acts as one of mechanisms for polyploidy was predicted as a late event in the majority of ESCC genome. Moreover, loss of heterozygosity events were more likely to occur in chromosomes harboring tumor suppressor genes in ESCC. The 40% of neutral loss of heterozygosity events was not a result of genome doubling, suggesting an alternative mechanism for neutral loss of heterozygosity formation. Importantly, deconstruction of copy number alterations extending to telomere revealed that telomere-bounded copy number alterations play a critical role for amplification/deletion of oncogenes/suppressor genes. For well-known genes SOX2, PIK3CA and TERT, nearly all of their amplifications were telomere bounded, which was further confirmed in a Japanese ESCC cohort. Furthermore, we provide evidence that karyotype evolution was mostly punctuated in ESCC. Collectively, our data reveal the potential biological role of whole genome doubling, neutral loss of heterozygosity and telomere-bounded copy number alterations, and highlight mecro-evolution in ESCC tumorigenesis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article